Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer Patients

Phase 1

Completed

Conditions: Neoplasms

First Posted Date: 2007-05-25

Last Posted Date: 2011-01-26

Lead Sponsor: Sanofi

Target Recruit Count: 22

Registration Number: NCT00479076

Locations: 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug

Phase 3

Terminated

Conditions: Obesity
Diabetes Mellitus Type 2

Interventions: Drug: Rimonabant
Drug: Placebo (for Rimonabant)
Drug: Anti-diabetic monotherapy

First Posted Date: 2007-05-25

Last Posted Date: 2016-06-06

Lead Sponsor: Sanofi

Target Recruit Count: 458

Registration Number: NCT00478595

Locations: 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients on Diet and Exercise

Phase 3

Terminated

Conditions: Obesity
Diabetes Mellitus Type 2

Interventions: Drug: Rimonabant
Drug: placebo (for Rimonabant)
Other: Diet and exercise

First Posted Date: 2007-05-25

Last Posted Date: 2016-06-08

Lead Sponsor: Sanofi

Target Recruit Count: 321

Registration Number: NCT00478972

Locations: 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan

Gulf Evaluation of VAlproate (Depakine Chrono) in maNia Study

Phase 4

Completed

Conditions: Bipolar Disorder

Interventions: Drug: depakine chrono

First Posted Date: 2007-05-23

Last Posted Date: 2008-12-19

Lead Sponsor: Sanofi

Target Recruit Count: 70

Registration Number: NCT00477373

Locations: 🇶🇦
Sanofi-aventis administrative office, Qatar, Qatar
🇴🇲
Sanofi-Aventis Administrative Office, Muscat, Oman

Practicability and Acceptability of Stylomax® in Children

Phase 3

Completed

Conditions: Growth Hormone Deficiency

Interventions: Drug: somatropine

First Posted Date: 2007-05-22

Last Posted Date: 2009-02-12

Lead Sponsor: Sanofi

Target Recruit Count: 12

Registration Number: NCT00476385

Locations: 🇫🇷
Sanofi-Aventis, Paris, France

Phase II Study of Teriflunomide as Adjunctive Therapy to Glatiramer Acetate in Subjects With Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo (for teriflunomide)
Drug: Teriflunomide
Drug: Glatiramer Acetate (GA)

First Posted Date: 2007-05-21

Last Posted Date: 2012-11-06

Lead Sponsor: Sanofi

Target Recruit Count: 123

Registration Number: NCT00475865

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, United Kingdom

Oxaliplatin + 5-FluoroUracil/LeucoVorin (5-FU/LV) (FOLFOX4) Versus Doxorubicin as Palliative Chemotherapy in Advanced Hepatocellular Carcinoma Patients

Phase 3

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Oxaliplatin + 5-Fluorouracil/Leucovorin
Drug: Doxorubicin

First Posted Date: 2007-05-10

Last Posted Date: 2010-09-20

Lead Sponsor: Sanofi

Target Recruit Count: 371

Registration Number: NCT00471965

Locations: 🇹🇭
Sanofi-Aventis Administrative Office, Bangkok, Thailand

Insulin Glulisine, Insulin Lispro and Insulin Glargine in Type 1 or 2 Diabetes Mellitus

Phase 3

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Insulin Glulisine
Drug: Lispro
Drug: Insulin Glargine

First Posted Date: 2007-04-30

Last Posted Date: 2009-09-15

Lead Sponsor: Sanofi

Target Recruit Count: 485

Registration Number: NCT00467376

Locations: 🇨🇳
Sanofi-Aventis, Beijing, China

Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

Phase 2

Completed

Conditions: Leukemia, Lymphocytic, Chronic

Interventions: Drug: alvocidib

First Posted Date: 2007-04-23

Last Posted Date: 2013-02-12

Lead Sponsor: Sanofi

Target Recruit Count: 165

Registration Number: NCT00464633

Locations: 🇺🇸
Sanofi-Aventis Investigational Site Number 840023, Ann Arbor, Michigan, United States
🇫🇷
Sanofi-Aventis Investigational Site Number 250002, Tours, France
🇺🇸
Sanofi-Aventis Investigational Site Number 840017, Indianapolis, Indiana, United States

and more 31 locations

Comparison of Efficacy and Safety of Rimonabant 5mg/Day or 20mg/Day Versus Placebo in Smoking Cessation

Phase 3

Completed

Conditions: Smoking Cessation

First Posted Date: 2007-04-23

Last Posted Date: 2010-12-10

Lead Sponsor: Sanofi

Target Recruit Count: 789

Registration Number: NCT00464165

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom

Home Terms & Conditions Privacy Policy